Results 21 to 30 of about 40,579 (221)

Protective effect of aqueous extract of Pleurotus eous against Dalton's lymphoma ascites tumor in mice

Journal of Agriculture and Food Research, 2023
The antitumor efficacy of Pleurotus eous aqueous extract (PEAE) was investigated both in vitro and in vivo. The MTT test was used to determine in vitro cytotoxicity against the Dalton's Lymphoma Ascites (DLA) cell line.
Vadivukkarasi Sasikumar, Sudha Govindan, Gayathri Rajendran, Archana Rajendran, Prasanna Ramani, Mirian Pateiro, José M. Lorenzo   +6 more
doaj   +1 more source

Organoid-on-Chip Technologies in Precision Oncology: Bridging Patient-Specific Tumor Biology and Physiologically Relevant Drug Screening

Organoids
The inadequacy of traditional preclinical oncology models, specifically two-dimensional (2D) monolayer cultures and murine in vivo systems, in predicting human drug responses has led to the development of patient-derived organoids (PDOs) and microfluidic
Muhammet Volkan Bulbul, Turan Demircan
doaj   +1 more source

Assessing individual head and neck squamous cell carcinoma patient response to therapy through integration of functional and genomic data

Scientific Reports
Even though head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, there are only two PD-1 targeted immunotherapies (pembrolizumab and nivolumab) and one tumor intrinsic EGFR targeted therapy (cetuximab) that are FDA ...
Daniel Bottomly, Chase Mathieson, Myles Vigoda, Sophia Jeng, Nathaniel Evans, Ashley Anderson, Aurora Blucher, Aletha Lesch, Christina Zheng, Ted Laderas, James Jacobs, Molly Kulesz-Martin, Shannon McWeeney   +12 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism

BMC Cancer, 2020
Background Despite an improvement of prognosis in breast and colon cancer, the outcome of the metastatic disease is still severe. Microevolution of cancer cells often leads to drug resistance and tumor-recurrence.
Jérôme Ruhnau, Jonas Parczyk, Kerstin Danker, Britta Eickholt, Andreas Klein   +4 more
doaj   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Novel cyanine dye as competitive ligand for probing the drug–nucleic acid interactions

Біофізичний вісник, 2020
Background: During the past decades, increasing attention has been given to elucidating the molecular details of interactions between the pharmacological agents and nucleic acids since the drug–DNA complexation may lead to impairment of DNA replication ...
O. Zhytniakivska, U. Tarabara, A. Kurutos, A. Zabrudska, K. Vus, V. Trusova, G. Gorbenko, T. Deligeorgiev   +7 more
doaj   +1 more source

Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling

eLife, 2022
The transcription factor TEAD, together with its coactivator YAP/TAZ, is a key transcriptional modulator of the Hippo pathway. Activation of TEAD transcription by YAP has been implicated in a number of malignancies, and this complex represents a ...
Mengyang Fan, Wenchao Lu, Jianwei Che, Nicholas P Kwiatkowski, Yang Gao, Hyuk-Soo Seo, Scott B Ficarro, Prafulla C Gokhale, Yao Liu, Ezekiel A Geffken, Jimit Lakhani, Kijun Song, Miljan Kuljanin, Wenzhi Ji, Jie Jiang, Zhixiang He, Jason Tse, Andrew S Boghossian, Matthew G Rees, Melissa M Ronan, Jennifer A Roth, Joseph D Mancias, Jarrod A Marto, Sirano Dhe-Paganon, Tinghu Zhang, Nathanael S Gray   +25 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy

Neoplasia: An International Journal for Oncology Research, 2021
Blockade of the PD-1/PD-L1 immunologic checkpoint using monoclonal antibodies has provided breakthrough therapies against cancer in the recent years. Nevertheless, intrinsic disadvantages of therapeutic antibodies may limit their applications.
Fengling Wang, Wenling Ye, Shuang Wang, Yongxing He, Haiyang Zhong, Yuwei Wang, Yongchang Zhu, Jianting Han, Zhitong Bing, Shaoping Ji, Huanxiang Liu, Xiaojun Yao   +11 more
doaj   +1 more source